Anatomic pathology market to reach US$ 61.1M by 2030

The global anatomic pathology market is set to reach US$ 61.1 Mn in revenues by 2030, according to a new market study by ESOMAR-certified market research firm, Future Market Insights (FMI).

The anatomic pathology market is subject to integrating medical informatics standards to meet specific healthcare requirements by curtailing costs and improvising on efficiency.

Pathology laboratories are on the verge of refurbishment as new-fangled disease diagnostic models are making a beeline therein.

As of now, lymphoma, breast cancer, colorectal cancer, prostate cancer, cervical cancer, and lung cancer are a part of anatomic pathology.

Key takeaways

• The instruments are subject to technological advancements, which would minimize errors. This factor is expected to drive the anatomic pathology market between 2022 and 2030
• Consumables are expected to hold the largest market share due to low cost, high availability, and good purchase rate of probes and reagents
• Academic research is bound to pick up pace in the forecast period owing to growing implementation of anatomic pathology in biomarker profiling and tumor examination
• Preference to personalized therapies is prompting putative biomarkers being discovered. This factor is expected to be one of the key growth drivers

“The anatomic pathology market is witnessing a continuous upswing on the part of biomarkers. This factor is expected to propel the development of anatomic pathology market” – says the FMI analyst.

Key participant insights
The key market players are focusing on technological upgradations and expansion strategies to keep themselves fiercely competitive.

For instance –

• In Jul 2020, Bio SB tabled its Fast Mohs PolyDetector Plus Detection System, which comes across as a super sensitive nonbiotin monovalent Fab micropolymer immunohistochemistry system to detect IVD antibodies for squamous cell carcinoma, basal cell carcinoma, and melanoma.
• In Jan 2019, Quest Diagnostics announced completion of acquisition of the US laboratory services business that belonged to Oxford Immunotec (the T-Spot and Accutix tick-borne disease testing services, since then, are part of Quest’s infectious disease testing services.
• In 2018, Leica Microsystems entered into a collaboration with Thermo Fisher to develop an integrated cryotomography workflow with regards to research.

The other players in the veterinary imaging market include

• Laboratory Corporation of America Holdings
• Sakura Finetek USA, Inc.
• F.Hoffmann-La Roche AG
• Cardinal Health, Inc.
• BioGenex
• NeoGenomics
• Agilent Technologies

The US continues to be one of the leading markets for anatomic pathology market globally. Strong presence of some of the leading players, combined with relatively easier funding for R&D will drive the US anatomic pathology market during the assessment period.

The Europe anatomic pathology market is also likely to grow at a brisk pace during the assessment period. The growth will remain concentrated in Western Europe, as has been the case traditionally.

Asia Pacific represents a high growth market for anatomic pathology stakeholders. Many countries in the region are renewing their focus on healthcare, as the current Covid-19 crisis has reinforced the necessity of a robust healthcare system. Future Market Insights